Возможные причины неэффективности генно-инженерных биологических препаратов при ревматоидном артрите и пути ее предотвращения
https://doi.org/10.14412/1996-7012-2012-725
Аннотация
Об авторе
Наталья Владимировна ЧичасоваDepartment of Rheumatology, Faculty for Postgraduate Training of Physicians
Литература
1. <div><p>Smolen J., van der Heijde D.M.F.M., Clair E.W. St. et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant Infliximab: Results from the ASPIRE trial. Arthr Rheum 2006; 54: 702-10.</p><p>Quinn M.A., Conaghan P.G., O’Connor P.J. et al. Very early treatment with Infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after Infliximab withdrawal: Results from a twelvemonth randomized , double-blind, placebocontrolled trial. Arthr Rheum 2005; 52: 27-35.</p><p>Visser H., Koen S.C., Breedveld F.C. et al. How to diagnose rheumatoid arthritis early: a predictor model for persistent (erosive) arthritis. Arthr Rheum 2002; 46: 357-65.</p><p>Smolen J.S., Landewе R., Breedveld F.C. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-3.</p><p>Клинические рекомендации. Ревматология. 2-е изд. Под ред. акад. РАМН Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2010; 738 с.</p><p>Каратеев Д.Е., Олюнин Ю.А. О классификации ревматоидного артрита. Науч.-практ. ревматол. 2008; 1: 5-16.</p><p>Prevoo M.L., van't Hof M.A., Kuper H.H. et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthr Rheum 1995; 38: 44-8.</p><p>Van Gestel A.M., Revoo M.L.L., van’t Hof M.A. et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with preliminaries American Colledge of Rheumatology and the World Health Organisation/International League against Rheumatism criteria. Arthr Rheum 1996; 39: 34-40.</p><p>Felson D.T., Anderson J.J., Lange M.L. et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthr Rheum 1998; 41: 1564-70.</p><p>Furst D.E., Keystone E.C., Fleischmann R. et al. Update consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010; 69(Suppl. I): i2-i29.</p><p>Quinn M.A., Conaghan P.G., O’Connor P.J. et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthr Rheum 2005; 52: 27-35.</p><p>Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F. et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Int Med 2007; 146: 406-15.</p><p>Bathn J.M., Martin R.W., Fleischmann R.M. et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.</p><p>St. Clair E.W., van der Heijde D.M., Smolen J.S. et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthr Rheum 2004; 50: 3432-43.</p><p>Vastesaeger N., Aletaha D., St. Clair W. et al. Matrix risk model for prediction of rapid radiographic progression in rheumatoid arthritis. Ann Rheum Dis 2008; 67(Suppl. II): 63.</p><p>Kristenen L.E., Kapetanovic M.C., Guffe A. et al. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology 2008; 47(4): 495-9.</p><p>Hyrych K.L., Watson K.D., Silman A.J. et al. Predictors of response to anti-TNF-therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006; 45(12): 1558-65.</p><p>Smolen J.S., Aletaha D., Bijlsma J.W. et al. Treating rheumatoid arthritis to target: recommendations of a international task force. Ann Rheum Dis 2010; 69: 631-7.</p><p>Aletaha D., Funovits J., Keystone E.C. et al. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthr Rheum 2007; 56: 3226-35.</p><p>Klareskog L., van der Heijde D., de Jager J.P. et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: doubleblind randomised controlled trial. Lancet 2004; 363: 675-81.</p><p>Curtis J.R., Yang S., Chen L. et al. Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analysis from the TEMPO trial. Ann Rheum Dis 2012; 71: 206-12.</p><p>Van der Heijde D., Shiff M., Keystone E.C. et al. Probability to achieve low disease activity at 52 weeks in rheumatoid arthritis (RA) patients treated with certolizumab pegol (CZP) depends on time to and level od initial response. Arthr Rheum 2009; 60: 992.</p><p>Pocock J.M., Vasconcelos J.C., Osor A.J. Assessment of anti-TNF-аlpha efficacy in rheumatoid arthritis: is 3 months sufficient. Rheumatology 2008; 47: 1073-6.</p><p>Kavanaugh A., Klareskog L., van der Heijde D. et al. Improvement in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate. Ann Rheum Dis 2008; 67: 1444-7.</p><p>Wit M.P.T., Smolen J.S., Gossec L. et al. Treating rheumatoid arthritis to target: the patient version of the international recommendations. Ann Rheum Dis 2011; publication on line April 2011, as 10.1136/ard 2010. 146662.</p><p>Wijbrandts C.A., Dijkgraaf M.G., Kraan M.C. et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann Rheum Dis 2008: 67: 1139-44.</p><p>St. Clair E.W., Wagner C.L., Fasanmade A.A. et al. The relationship of serum infliximab concentration to clinical improvement in rheumatoid arthritis/ Results from ATTRACT, a multicenter, randomized, double-blind placebo-controlled trial. Arthr Rheum 2002; 46: 1451-9.</p><p>Mileman D., Meric J.C., Paintaud G. et al. Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis. Arthr Res Ther 2009; 11(6): R178.</p><p>Jamnitski A., Krieckaert C.L., Nurmohamed M.T. et al. Patients nonresponding to etanercept obtain lower etaner-cept concentration compared with responding patients. Ann Rheum Dis 2012; 71: 88-91.</p><p>Feldmann M., Maini R.N. Anti-TNF therapy of rheumatoid arthritis: what have we learned. Ann Rev Immunol 2001; 19: 163-96.</p><p>Maini R.N., Breedveld F.C., Kalden J.R. Therapeutic efficacy of multiple intravenous infusion of anti-tumor necrosis factor monoclonal antibody combined with low-dose wekly methotrexate in rheumatoid arthritis. Arthr Rheum 1998; 41: 1552-63.</p><p>Pavelka K., Jarosova K., Suchy D. et al. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double-blind study failed to confirm its efficacy. Ann Rheum Dis 2009; 68: 1285-9.</p><p>Flendrie M., Creemers M.C.W., Welsing P.M.J. et al. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003; 62(Suppl. 2): ii30-3.</p><p>Geborek P., Crnkic M., Petersson I.F. et al. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002; 61(9): 793-8.</p><p>Wendling D., Materne G.-E., Michel F. et al. Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice. J Bone Spine 2005; 72: 309-12.</p><p>Maini R.N., Breedveld F.C., Kalden J.R. et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthr Rheum 2004; 50(4): 1051-65.</p><p>Ostergaard M., Unkerskov J., Linde L. et al. Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database. Scand J Rheum 2006; 36: 151-4.</p><p>Yazici Y., Krasnokutsky S., Barnes J.P. et al. Changing Patterns of Tumor Necrosis Factor Inhibitor Use in 9074 Patients with Rheumatoid Arthritis. J Rheum 2009; 36; 907-13.</p><p>Brocq O., Roux C.H., Albert C. et al. TNF antagonist continuation rates in 422 patients with inflammatory joint disease. J Bone Spine 2007; 74: 148-54.</p><p>Cruyssen B.V., Durez P., Westhovens R. et al. Seven year follow-up of infliximab in rheumatoid arthritis patients refractory to multiple DMARDs treatment: Attrition and long-term clinical effect. Arthr Res Ther 2006; 8: R112.</p><p>Westhovens R., Yocum D., Han J. et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthr Rheum 2006; 54: 1075-86.</p><p>Nam J.L., Winthrop K.L., Vollenhoven R.F. et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendation for the management of RA. Ann Rheum Dis 2010; 69: 976-86.</p><p>Carmona L., Ortiz A., Abad M.A. How good is to switch between biologics? A systematic review of the literature. Acta Rheum Port 2007; 32: 113-28.</p><p>Lopez-Olivo M.A., Roundtree A.K., Ortiz Z. Switching between anti-TNF agents treatments for rheumatoid arthritis: a systematic review. Ann Rheum Dis 2007; 66: 189.</p></div><br />
Рецензия
Для цитирования:
Чичасова Н.В. Возможные причины неэффективности генно-инженерных биологических препаратов при ревматоидном артрите и пути ее предотвращения. Современная ревматология. 2012;6(2):31-41. https://doi.org/10.14412/1996-7012-2012-725
For citation:
Chichasova N.V. Possible reasons for the inefficacy of genetically engineered biological agents in rheumatoid arthritis and ways of its prevention. Modern Rheumatology Journal. 2012;6(2):31-41. (In Russ.) https://doi.org/10.14412/1996-7012-2012-725
Просмотров: 1564
Послать статью по эл. почте 